Navigation Links
Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema

Company anticipates second quarter BLA filing for C1-inhibitor replacement therapy

NEW YORK, March 14, 2007 /PRNewswire-FirstCall/ -- Lev Pharmaceuticals, Inc. (Lev) today announced positive results from its pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH) for the acute treatment of hereditary angioedema (HAE). In the acute study, which is part of the company's CHANGE trials (C1-inhibitor in Hereditary Angioedema Nanofiltration Generation evaluating Efficacy), the protocol-defined primary endpoint was reached, showing a clinically and statistically significant reduction in the time to sustained relief of acute HAE symptoms. Based on the positive results of this study, the Company intends to submit a Biologics License Application to the Food and Drug Administration in the second quarter of 2007. HAE, or hereditary C1-inhibitor deficiency, is a rare and life-threatening inflammatory condition for which there is currently no FDA-licensed acute therapy in the United States.

In the double-blind study, which was conducted at 20 medical centers in the United States, a total of 71 patients were randomized to either C1-INH or placebo. The primary endpoint was met using the protocol-defined intent to treat analysis, with a median time to sustained symptom relief of 2.0 hours for patients receiving C1-INH compared to greater than four hours, the maximum evaluation period, for patients receiving placebo (p=0.026). Sustained symptom relief was defined as subject-reported symptom relief at three consecutive 15 minute intervals following treatment.

"I'm very pleased with the successful outcome of the CHANGE study for the acute treatment of HAE, and I'm hopeful that this will lead to the much-needed availability of C1-inhibitor therapy for this underserved patient population," said Bruce Zuraw, M.D., Professor of Medicine at the University of California San Diego and Principal Investigator of the Ph
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/4/2015)... , September 4, 2015 ... Vaccines  Allergic Rhinitis drugs - ... Where is the market for allergic rhinitis ... market? Visiongain ,s new report shows you potential ... and prospects. Our 326 page report provides ...
(Date:9/4/2015)... Sep. 04, 2015 Research and ... "Investigation Report on China,s Sodium Ibandronate Market, 2010-2019" ... in the clinic under the trade name of Bondronat in ... in 1996, sodium ibandronate was approved by the FDA ... osteoporosis under the trade name of Boniva. However, since drug ...
(Date:9/4/2015)... 2015 Hutchison China MediTech ... MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully ... ("POC") trial of fruquintinib in patients with advanced ... China .  The top-line results demonstrated ... primary efficacy endpoint of progression free survival ("PFS"). ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... EAST BRUNSWICK, N.J., Oct. 25 Savient Pharmaceuticals, Inc. (Nasdaq: ... host a conference call on Tuesday, October 26, 2010 at ... detail around its KRYSTEXXA™ launch plans. ... will host a live conference call on October 26, 2010 ...
... The National Community Pharmacists Association (NCPA) today announced ... by Cardinal Health , which found that independent community ... in 2009 despite a stagnant economy, the growing influence ... and the questionable business practices of pharmacy benefit managers ...
Cached Medicine Technology:Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time 2Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time 3NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 2NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 3NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges 4
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts ... the Year” awards at this year’s Microsoft Worldwide Partner Conference that was held ... the Year” Award Winner for Data Platform services, the 2015 HP and Microsoft ...
(Date:9/4/2015)... ... 04, 2015 , ... “Getting away from the daily stressors and distractions of ... strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons Resort ... island’s only Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel in ...
(Date:9/4/2015)... Pass, OR (PRWEB) , ... September 04, 2015 ... ... that markets a line of personal humidifying medical devices, announced its only mission ... climate, explains Bio-Logic Aqua® Research Founder Sharon Kleyne, body water evaporation is becoming ...
(Date:9/4/2015)... ... September 04, 2015 , ... Having access to a doctor ... to an increasing amount of unnecessary emergency room visits which affects hospitals’ abilities to ... country’s health bill. Fortunately, a solution to alleviate this problem has recently presented itself, ...
(Date:9/4/2015)... ... September 04, 2015 , ... Steven Winter Associates, Inc., ... has been selected for the Residential Award of Merit by the Connecticut Green ... Chosen from a highly competitive field of submissions, the net-zero energy residence will ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2
... Cancer Center President Ronald DePinho, M.D., has been elected to ... most prestigious accolades in the United States bestowed in the ... member of the MD Anderson faculty to be recognized with ... society of distinguished scholars engaged in scientific and engineering research. ...
... New York, NY(May 1, 2012) Large majorities of ... primary care, according to a new national survey, "How ... released today by the John A. Hartford Foundation, a ... the Hartford Institute for Geriatric Nursing at New York ...
... To better understand the signaling pathways active in sarcomas, ... proteomics to characterize a family of protein enzymes that ... biology of cancer. The tyrosine kinases they identified, the ... and survival of sarcomas. Sarcomas are relatively rare ...
... people who take a class of common blood pressure ... researchers have found. The finding suggests that ACE ... could be valuable tools for treating or preventing post-traumatic ... May 1 in the Journal of Clinical Psychiatry. ...
... patient education process may provide an antidote to the ... before and after an operation, according to a new ... Journal of the American College of Surgeons. ... a 30-minute preparation video reported less anxiety about the ...
... of teenagers, friends can have as much effect on ... to prevention researchers. "Among friendship groups with ,good ... are consistent and aware of your whereabouts, and your ... (children,s) whereabouts, then you are less likely to use ...
Cached Medicine News:Health News:UT MD Anderson President Ronald DePinho elected to National Academy of Sciences 2Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 2Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 3Health News:Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival 2Health News:Blood pressure drugs linked with lower PTSD symptoms 2Health News:Study finds that patient education videos viewed before an operation may benefit patients 2Health News:Study finds that patient education videos viewed before an operation may benefit patients 3Health News:It takes a village to keep teens substance free 2
... The Polaris system delivers the ... cost effective and easy to use, ... level of precision measurement with unprecedented ... both active and passive tools, the ...
Penfield Dissector #4...
Leroy scalp clips, sterile, disposable, plastic, infant size, ten clips/package....
Disposable scalp clip applier, comes loaded with 12 Leroy-Raney clips, ergonomic, easy to handle and position the clip....
Medicine Products: